Abstract: The present invention relates to an isolated peptide consisting of a sequence of 3 to 39 amino acids derived from the amino acid sequence SEQ ID NO: 1, said peptide having a sequence of amino acids selected from the group consisting of: a) sequences of 3 to 39 amino acids comprising at least the residues 6 to 8 of SEQ ID NO: 1, and b) sequences of 3 to 39 amino acids having at least 70% identity with said sequence in a).

Abstract: A method for imaging a material to atomic scale by means of a field-ion microscope having a vacuum chamber configured to accommodate the material prepared in the form of a tip and an imaging gas, and an ion detector is provided. The method includes application of a DC electrical potential (VDC) and of a pulsed electrical potential, of which the maximum pulse value is denoted Vimp, so that the tip erodes for a potential value equal to VDC+Vimp; acquisition, by the detector between at least two pulses of the pulsed potential, of series of at least two ion images of the impacts of the ions repelled by the tip onto the detector; and calculation of a quantity characteristic of a trend of the erosion of the tip based on the series of ion images acquired and the adjustment, between each series of images, of the values of VDC and of Vimp such that the quantity characteristic of the trend and the ratio VDC/Vimp remain constant.

Abstract: Disclosed is a method and a device for retrieving, from an object A, elements G present in a matrix M, the method including at least the following steps: bringing said abject A into contact with a dense fluid Fd with a molar mass greater than 2 g mol?1 under temperature T1 and pressure P1 conditions suitable for transforming the intergranular phase and for releasing the elements G, modifying the temperature T2 and/or pressure P2 values to stop the reaction transforming the intergranular phase, and recovering the elements G separated front the matrix M.

Abstract: The present invention relates to a method for detecting or quantifying deoxyribonucleic acid (DNA) of human immunodeficiency virus 2 (HIV-2) in a sample containing DNA comprising: a) performing a real-time polymerase chain reaction (PCR) on the sample, or a fraction thereof comprising DNA, with at least two sets of primers and probe each respectively comprising two primers and a labeled probe for the detection or quantification of HIV-2 DNA, at least one of the sets is selected from the group consisting of: a set comprising a primer comprising or consisting of a sequence SEQ ID NO: 1 or a sequence having al least 90% identity to SEQ ID NO: 1, a primer comprising or consisting of a sequence SEQ ID NO: 2 or a sequence having 90% identity to SEQ ID NO: 2 or the complement of these sequences, and a labeled probe comprising or consisting of a sequence SEQ ID NO: 3, or a sequence having at least 90% identify to SEQ ID NO: 3 or the complement of these sequences, and a set comprising a primer comprising or consisting

Abstract: An austenitic alloy based on nickel, chromium and iron, and having a high aluminum content, intended for use at a given operating temperature (Ts) between 900° C. and 1200° C., the alloy comprising the following elements, in weight percent: chromium between 20% and 32%, nickel between 30% and 60%, aluminum between 3.5% and 6%, carbon between 0.4% and 0.7%, titanium between 0.05% and 0.3%, niobium and/or tantalum between 0.6% and 2%, an element, composed of at least one rare earth and/or hafnium, between 0.002% and 0.1%, silicon between 0 and 0.5%, manganese between 0 and 0.5%, tungsten between 0 and 2%, and iron as the balance of the elements in the alloy. The alloy has less than 1% by volume of an intermetallic B2-NiAl phase and less than 1% by volume of an alpha prime phase rich in chromium, after subjecting the alloy to an operating temperature (Ts).

Abstract: The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of a ClpB protein or an effective amount of a bacterium that expresses the ClpB protein.

Abstract: The inventors demonstrate that the phosphatase and hydrolase domains of soluble epoxide hydrolase (sEH) regulate the cardiovascular calcification process and revealed that inhibition of the phosphatase domain of sEH could represent a new pharmacological target in the prevention of cardiovascular calcification. The present invention thus relates to a therapeutically effective amount of an inhibitor of phosphatase activity of soluble epoxide hydrolase for use in a method of treating cardiovascular calcification in a subject in need thereof.

Abstract: Provided herein are methods and kits for labeling endonuclease-treated cells. The methods comprise: contacting the cells to be labelled with at least one endonuclease suitable for targeting a genomic region of interest, and first and second nucleic acids suitable for introducing one or more silent (or optionally non-silent) mutation(s) in the genomic region by homology-directed repair (HDR). The mutation(s) introduced by the first nucleic acid differ from the mutation(s) introduced by the second nucleic acid.

Abstract: The present invention relates to method of preventing, treating or attenuating obesity-related manifestations in a human or non-human mammal subject in need thereof, said method comprising orally administering to the subject a composition comprising an effective amount Hafnia alvei probiotics; wherein said obesity-related parameters are selected from the group of hyperphagia, increased fat mass on lean mass ratio, increased waist circumference, postprandial hyperglycemia, fasting hyperglycemia and hypercholesterolemia.

Abstract: Methods of treating inflammation, in particular obesity, inducing satiation, prolonging satiety, and stimulating weight loss in a subject in need thereof, including the administration of a Brassicaceae protein extract. The Brassicaceae protein extract may be administered in the form of a dietary supplement or a food composition, either of which may include at least one additional ingredient.

Abstract: A composition essentially made of a Hafnia alvei probiotic strain expressing the ClpB protein; wherein the ClpB protein is in an amount of at least 0.7% (w/w) in weight relative to the total weight of the composition; and the ratio of the total number of Hafnia alvei Colony Forming Units to the total Hafnia alvei cell number ranges from 10?4 to 0.8. Also, oral dosage forms, namely gastro-resistant capsules including the composition of essentially made of a Hafnia alvei probiotic strain expressing the ClpB protein.

Abstract: Disclosed is a method and system for recovering at least rare earth elements from within an object A consisting of at least one first rare earth portion or a mixture of rare earth elements and a second metal portion. The method includes a solvothermal treatment step that places the object in contact with a fluid for causing at least one rare earth portion and/or mixture of rare earth elements and the metal portion to oxidize in order to separate same, the value of the reaction temperature Tr is selected according to the nature of the object, the reaction following a R-M?R(X)x+M(X)y scheme, where R is the rare earth element or a mixture of rare earth elements, M is the transition metal, and (X) is a group which depends on the fluid used.

Abstract: Methods of treating inflammation, in particular obesity, inducing satiation, prolonging satiety, and stimulating weight loss in a subject in need thereof, including the administration of a Brassicaceae protein extract. The Brassicaceae protein extract may be administered in the form of a dietary supplement or a food composition, either of which may include at least one additional ingredient.

Abstract: A laser source for emitting a group of pulses, includes a primary laser source suitable for emitting at least one primary laser pulse; at least one interferometer suitable for forming, from the primary laser pulse, a plurality of secondary laser pulses, each interferometer comprising at least one delay line allowing two secondary laser pulses to be temporally separated, by a delay comprised between 50 ps and 10 ns; and a single-mode amplifying optical fiber intended to receive the secondary laser pulses, in order to form as output a group of spatially superposed pulses.

Abstract: The present invention relates to ClpB expressing bacteria and their impact on obesity. The present invention relates to bacterial ClpB protein and ClpB expressing bacteria and their impact on eating disorders. The invention further relates to compositions comprising antibiotic directed against at least one ClpB expressing bacterium as well as probiotics not expressing ClpB protein and their use in the treatment or prevention of eating disorders. The invention also relates to diagnostic tools for determining whether a subject is likely to respond to a method of treating eating disorders and to methods of immunization against eating disorders.

Abstract: The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of a ClpB protein or an effective amount of a bacterium that expresses the ClpB protein.

Abstract: Polypeptides and proteins that include a fragment of a ClpB protein and compositions therefrom. Methods of treatment and/or prevention of inflammation, in particular overweight and/or obesity-related diseases and disorders, with the polypeptides and proteins. Also, methods of inducing satiation, prolonging satiety, reducing meal size, reducing food intake, controlling weight gain and stimulating weight loss with the polypeptides and proteins.

Abstract: An austenitic alloy based on nickel, chromium and iron, and having a high aluminum content, intended for use at a given operating temperature (Ts) between 900° C. and 1200° C., the alloy comprising the following elements, in weight percent: chromium between 20% and 32%, nickel between 30% and 60%, aluminum between 3.5% and 6%, carbon between 0.4% and 0.7%, titanium between 0.05% and 0.3%, niobium and/or tantalum between 0.6% and 2%, an element, composed of at least one rare earth and/or hafnium, between 0.002% and 0.1%, silicon between 0 and 0.5%, manganese between 0 and 0.5%, tungsten between 0 and 2%, and iron as the balance of the elements in the alloy. The alloy has less than 1% by volume of an intermetallic B2-NiAl phase and less than 1% by volume of an alpha prime phase rich in chromium, after subjecting the alloy to an operating temperature (Ts).

Abstract: The invention relates to a placental growth factor (PlGF) to be used as a drug in the prevention and/or treatment of fetal alcohol syndrome disorders (FASD) selected from the group comprising fetal alcohol syndrome (FAS), cerebrovascular disease, and growth retardation in a subject exposed to alcohol in utero. The invention also relates to a pharmaceutical composition or a product comprising the PlGF for the same therapeutic uses.

Abstract: Embodiments of the present disclosure relate to an isolated peptide consisting of a sequence of 3 to 39 amino acids derived from the amino acid sequence SEQ ID NO: 1, said peptide having a sequence of amino acids selected from the group consisting of: a) sequences of 3 to 39 amino acids comprising at least the residues 6 to 8 of SEQ ID NO: 1, and b) sequences of 3 to 39 amino acids having at least 70% identity with said sequence in a).